当前位置: X-MOL 学术Chem. Soc. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Half a century of amyloids: past, present and future.
Chemical Society Reviews ( IF 40.4 ) Pub Date : 2020-07-07 , DOI: 10.1039/c9cs00199a
Pu Chun Ke 1 , Ruhong Zhou , Louise C Serpell , Roland Riek , Tuomas P J Knowles , Hilal A Lashuel , Ehud Gazit , Ian W Hamley , Thomas P Davis , Marcus Fändrich , Daniel Erik Otzen , Matthew R Chapman , Christopher M Dobson , David S Eisenberg , Raffaele Mezzenga
Affiliation  

Amyloid diseases are global epidemics with profound health, social and economic implications and yet remain without a cure. This dire situation calls for research into the origin and pathological manifestations of amyloidosis to stimulate continued development of new therapeutics. In basic science and engineering, the cross-β architecture has been a constant thread underlying the structural characteristics of pathological and functional amyloids, and realizing that amyloid structures can be both pathological and functional in nature has fuelled innovations in artificial amyloids, whose use today ranges from water purification to 3D printing. At the conclusion of a half century since Eanes and Glenner's seminal study of amyloids in humans, this review commemorates the occasion by documenting the major milestones in amyloid research to date, from the perspectives of structural biology, biophysics, medicine, microbiology, engineering and nanotechnology. We also discuss new challenges and opportunities to drive this interdisciplinary field moving forward.

中文翻译:

淀粉样蛋白的半个世纪:过去、现在和未来。

淀粉样蛋白疾病是一种全球性流行病,具有深远的健康、社会和经济影响,但仍无法治愈。这种严峻的形势需要研究淀粉样变性的起源和病理表现,以刺激新疗法的持续开发。在基础科学和工程中,跨β结构一直是病理性和功能性淀粉样蛋白结构特征背后的一条恒定线索,认识到淀粉样蛋白结构本质上既可以是病理性的,也可以是功能性的,这推动了人工淀粉样蛋白的创新,其当今的用途广泛从水净化到3D打印。自 Eanes 和 Glenner 对人类淀粉样蛋白的开创性研究结束半个世纪以来,这篇综述从结构生物学、生物物理学、医学、微生物学、工程和纳米技术的角度记录了迄今为止淀粉样蛋白研究的主要里程碑,以纪念这一时刻。 。我们还讨论了推动这一跨学科领域向前发展的新挑战和机遇。
更新日期:2020-08-04
down
wechat
bug